Kelberman Daniel, Dattani Mehul T
Developmental Endocrinology Research Group, Institute of Child Health, London, UK.
Horm Res. 2007;68 Suppl 5:138-44. doi: 10.1159/000110610. Epub 2007 Dec 10.
The last 15 years have witnessed an explosion in our knowledge of hypothalamo-pituitary development, acquired mainly from naturally-occurring and transgenic animal models. A complex genetic cascade dictates organ commitment, cell differentiation and cell proliferation within the anterior pituitary. Mutations in genes encoding both signalling molecules and transcription factors have been implicated in the aetiology of hypopituitarism, with or without other syndromic features, in mice and humans. These include HESX1, LHX3, LHX4, PROP1, POU1F1 and, more recently, SOX3 and SOX2. Phenotypes associated with mutations in genes encoding these factors and their inheritance may be highly variable.
Mutations in genes implicated in early pituitary development may be associated with extrapituitary phenotypes, which in turn may be highly variable. For example, dominant and recessive mutations in HESX1 may be associated with septo-optic dysplasia, combined pituitary hormone deficiency (CPHD) and isolated growth hormone (GH) deficiency. Duplications and polyalanine expansions within the transcription factor SOX3 have recently been described in association with infundibular hypoplasia, hypopituitarism and variable mental retardation, whilst mutations in SOX2 are associated with variable hypopituitarism in association with learning difficulties, oesophageal atresia and anophthalmia. Mutations within the LIM domain gene LHX3 are associated with a recessive phenotype characterised by deficiencies in GH, thyroid-stimulating hormone (TSH), luteinising hormone (LH) and follicle-stimulating hormone (FSH) with sparing of the corticotrophs, in association with a short stiff neck with limited rotation. A single mutation has been described within the LHX4 gene, and is dominantly inherited and associated with GH, TSH and adrenocorticotrophic hormone (ACTH) deficiency. The mutation is associated with a hypoplastic anterior pituitary, an undescended posterior pituitary and pointed cerebellar tonsils. PROP1 and POU1F: Recessive mutations within the pituitary-specific transcription factor Prophet of Pit1, or PROP1, are associated with CPHD (GH, prolactin [PRL] and TSH deficiency with additional LH and FSH deficiency). An enlarged sella turcica with appearances suggestive of a pituitary tumour is occasionally observed in association with PROP1 mutations. ACTH deficiency can evolve in a number of patients, reflecting the need for constant review of the phenotype. Mutations within POU1F1 are associated with GH, TSH and PRL deficiencies, with the TSH deficiency being highly variable. Magnetic resonance imaging reveals either a normal or hypoplastic anterior pituitary. Mutations may be either dominantly or recessively inherited, and the R271W mutation, which is believed to act as a dominant negative mutation, represents a mutational 'hot spot'.
In the future, genetic analysis together with functional analysis of the mutations at the protein level will have a greater role to play in understanding the mechanisms leading to particular hypopituitary phenotypes and in predicting the evolution of these disorders. However, there is no substitute for careful delineation of the clinical, biochemical and neuroradiological phenotype prior to undertaking genetic studies.
过去15年见证了我们对下丘脑 - 垂体发育知识的激增,这些知识主要来自自然发生的和转基因动物模型。一个复杂的基因级联反应决定了垂体前叶内的器官定向、细胞分化和细胞增殖。编码信号分子和转录因子的基因突变已被证明与小鼠和人类垂体功能减退的病因有关,无论是否伴有其他综合征特征。这些基因包括HESX1、LHX3、LHX4、PROP1、POU1F1,以及最近发现的SOX3和SOX2。与这些因子编码基因的突变及其遗传相关的表型可能高度可变。
与早期垂体发育相关基因的突变可能与垂体外表型有关,而这些表型反过来也可能高度可变。例如,HESX1的显性和隐性突变可能与视隔发育不良、联合垂体激素缺乏症(CPHD)和孤立性生长激素(GH)缺乏症有关。转录因子SOX3内的重复和多聚丙氨酸扩展最近被描述与漏斗部发育不全、垂体功能减退和可变的智力发育迟缓有关,而SOX2的突变与伴有学习困难、食管闭锁和无眼症的可变垂体功能减退有关。LIM结构域基因LHX3内的突变与一种隐性表型有关,其特征为GH、促甲状腺激素(TSH)、促黄体生成素(LH)和促卵泡激素(FSH)缺乏,促肾上腺皮质激素细胞不受影响,同时伴有颈部短而僵硬且活动受限。LHX4基因内已描述了一个单一突变,其为显性遗传,与GH、TSH和促肾上腺皮质激素(ACTH)缺乏有关。该突变与垂体前叶发育不全、垂体后叶未降和小脑扁桃体尖有关。PROP1和POU1F:垂体特异性转录因子Pit1的预言者(PROP1)内的隐性突变与CPHD(GH、催乳素[PRL]和TSH缺乏,伴有额外的LH和FSH缺乏)有关。偶尔观察到与PROP1突变相关的蝶鞍扩大,外观提示垂体肿瘤。一些患者可能会出现ACTH缺乏,这反映了需要对表型进行持续评估。POU1F1内的突变与GH、TSH和PRL缺乏有关,TSH缺乏高度可变。磁共振成像显示垂体前叶正常或发育不全。突变可能是显性或隐性遗传,R271W突变被认为是一种显性负性突变,是一个突变“热点”。
未来,基因分析以及蛋白质水平突变的功能分析将在理解导致特定垂体功能减退表型的机制以及预测这些疾病的发展方面发挥更大作用。然而,在进行基因研究之前,仔细描述临床、生化和神经放射学表型是无可替代的。